---
layout: default
title: Prednisolone
description: "Prednisolone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 138
evidence_level: L3
indication_count: 10
---

# Prednisolone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Prednisoloneï¼šå¾æ¿•ç–¹æ¨£çš®è†šç‚åˆ°æ–‘ç¦¿ (Alopecia Areata)

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Prednisolone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Prednisolone åŸæœ¬ç”¨æ–¼æ²»ç™‚æ¿•ç–¹æ¨£çš®è†šç‚ç­‰éæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ–‘ç¦¿ (Alopecia Areata)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **14 å€‹è‡¨åºŠè©¦é©—**å’Œ **8 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ¿•ç–¹æ¨£çš®è†šç‚ã€èŸ²å’¬å‚·ã€å°¿å¸ƒç–¹ã€çš®è†šæ”ç™¢åŠéæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopecia areataã€alopecia mucinosaã€telogen effluviumã€Quinquaud's folliculitis decalvansã€alopecia antibody deficiencyã€hereditary hypotrichosis with recurrent skin vesiclesã€alopecia-intellectual disability-hypergonadotropic hypogonadism syndromeã€atrichia with papular lesionsã€prolapse of lacrimal glandã€Sjogren syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 20 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia areata</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒPrednisolone æ˜¯ä¸€ç¨®é¡å›ºé†‡è—¥ç‰©ï¼Œå…·æœ‰æŠ—ç‚å’Œå…ç–«èª¿ç¯€ä½œç”¨ã€‚
å…¶æˆåˆ†åœ¨æ²»ç™‚éæ•æ€§å’Œç™¼ç‚æ€§çš®è†šç–¾ç—…ä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼æ–‘ç¦¿é€™é¡è‡ªé«”å…ç–«æ€§ç–¾ç—…ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT03616964](https://clinicaltrials.gov/study/NCT03616964) | Phase 3 | å®Œæˆ | 778 | ç ”ç©¶ Baricitinib åœ¨ SLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚ |
| [NCT05162586](https://clinicaltrials.gov/study/NCT05162586) | Phase 2 | å®Œæˆ | 456 | ç ”ç©¶ Enpatoran åœ¨ SLE å’Œ CLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚ |
| [NCT04835441](https://clinicaltrials.gov/study/NCT04835441) | Phase 2 | å®Œæˆ | 76 | ç ”ç©¶ ALPN-101 åœ¨ä¸­é‡åº¦ SLE æ‚£è€…ä¸­çš„æ•ˆæœã€‚ |
| [NCT03843125](https://clinicaltrials.gov/study/NCT03843125) | Phase 3 | çµ‚æ­¢ | 1147 | é•·æœŸç ”ç©¶ Baricitinib åœ¨ SLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚ |
| [NCT07101471](https://clinicaltrials.gov/study/NCT07101471) | N/A | å®Œæˆ | 296 | è©•ä¼° RhofanibÂ® (Tofacitinib) åœ¨æ–‘ç¦¿æ‚£è€…ä¸­çš„å®‰å…¨æ€§å’Œæ•ˆæœã€‚ |
| [NCT01167946](https://clinicaltrials.gov/study/NCT01167946) | Phase 4 | å®Œæˆ | 42 | ç ”ç©¶å¤§åŠ‘é‡å£æœé¡å›ºé†‡åœ¨åš´é‡æ–‘ç¦¿ä¸­çš„å®‰å…¨æ€§å’Œæ•ˆæœã€‚ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [37870096](https://pubmed.ncbi.nlm.nih.gov/37870096/) | 2023 | Meta-analysis | The Cochrane database of systematic reviews | æ–‘ç¦¿çš„æ²»ç™‚åŒ…æ‹¬å…ç–«æŠ‘åˆ¶åŠ‘ã€ä¿ƒé€²æ¯›é«®ç”Ÿé•·çš„è—¥ç‰©å’Œæ¥è§¸å…ç–«ç™‚æ³•ã€‚ |
| [30191561](https://pubmed.ncbi.nlm.nih.gov/30191561/) | 2019 | Systematic Review | The Australasian journal of dermatology | ç³»çµ±æ€§æ²»ç™‚åœ¨æ–‘ç¦¿ä¸­çš„æ‡‰ç”¨åŠå…¶æ•ˆæœã€‚ |
| [37992355](https://pubmed.ncbi.nlm.nih.gov/37992355/) | 2023 | Review | Dermatology practical & conceptual | ç ”ç©¶é¡å›ºé†‡è„ˆè¡ç™‚æ³•åœ¨æ–‘ç¦¿ä¸­çš„æ•ˆæœåŠå‰¯ä½œç”¨ã€‚ |
| [35986630](https://pubmed.ncbi.nlm.nih.gov/35986630/) | 2022 | Retrospective Study | Dermatologic therapy | ç ”ç©¶ç”²åŸºå¼·çš„æ¾é¾å–®ç¨æˆ–èˆ‡ç”²æ°¨è¶å‘¤è¯åˆæ²»ç™‚å»£æ³›æ–‘ç¦¿çš„æ•ˆæœã€‚ |
| [15692475](https://pubmed.ncbi.nlm.nih.gov/15692475/) | 2005 | RCT | Journal of the American Academy of Dermatology | ç³»çµ±æ€§é¡å›ºé†‡ä½œç‚ºè„ˆè¡ç™‚æ³•åœ¨æ–‘ç¦¿ä¸­çš„æ‡‰ç”¨ã€‚ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. alopecia mucinosa</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. telogen effluvium</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Quinquaud's folliculitis decalvans</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. alopecia antibody deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hereditary hypotrichosis with recurrent skin vesicles</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atrichia with papular lesions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. prolapse of lacrimal gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. idiopathic steroid-sensitive nephrotic syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.86%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è£½å­—ç¬¬000590è™Ÿ | æ¨‚çˆ¾çˆ½è»Ÿè† | è»Ÿè†åŠ‘ | æ¿•ç–¹æ¨£çš®è†šç‚ã€èŸ²å’¬å‚·ã€å°¿å¸ƒç–¹ã€çš®è†šæ”ç™¢åŠéæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ç­‰ |
| å…§è¡›è—¥è£½å­—ç¬¬000711è™Ÿ | æ™®åŠ›å¤šå¯§éŒ  | éŒ åŠ‘ | é¢¨æ¿•æ€§ç–¾æ‚£ã€æ”¯æ°£ç®¡æ°£å–˜ã€è…ç‚ç—‡å€™ç¾¤ã€éæ•æ€§çš®è†šç–¾æ‚£ |
| å…§è¡›è—¥è£½å­—ç¬¬004492è™Ÿ | â€œè¯ç³â€è¢ªé¢¨æ¿•é¾éŒ  | éŒ åŠ‘ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€çš®è†šç‚ã€æ”¯æ°£ç®¡ç‚ã€æ°£å–˜ã€éæ•æ€§ç–¾æ‚£ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šPrednisolone èˆ‡å¤šç¨®è—¥ç‰©æœ‰ä¸­ç­‰ç¨‹åº¦çš„äº¤äº’ä½œç”¨ï¼Œä¾‹å¦‚ Zidovudineã€Abametapir (topical)ã€Isotretinoin ç­‰ã€‚
- **ä¸»è¦äº¤äº’ä½œç”¨**ï¼šèˆ‡ Adalimumab æœ‰é‡å¤§äº¤äº’ä½œç”¨ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å»¶é•·çš®è³ªé¡å›ºé†‡ä½œç”¨ï¼Œå¢åŠ å‰¯ä½œç”¨é¢¨éšª
- å»ºè­°ï¼šé¿å…é«˜åŠ‘é‡ç”˜è‰



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Latent Tuberculosis** ğŸŸ¡ Moderate
- In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid ther...

**Fibrosis** ğŸŸ¡ Moderate
- Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these p...

**Psychotic Disorders** ğŸŸ¡ Moderate
- Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be adminis...

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corti...

*å¦æœ‰ 18 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Prednisolone åœ¨æ–‘ç¦¿çš„æ²»ç™‚ä¸­å·²æœ‰å¤šå€‹è‡¨åºŠè©¦é©—å’Œæ–‡ç»æ”¯æŒï¼Œé¡¯ç¤ºå…¶å¯èƒ½çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²ä¸€æ­¥çš„æ©Ÿè½‰ç ”ç©¶ä»¥ç¢ºèªå…¶åœ¨æ–‘ç¦¿ä¸­çš„ä½œç”¨æ©Ÿåˆ¶
- ç‰¹å®šæ—ç¾¤çš„å®‰å…¨æ€§ç›£æ¸¬è¨ˆç•«


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Lornoxicam]({{ "/drugs/lornoxicam/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Prednisoloneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/prednisolone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_prednisolone,
  title = {Prednisoloneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/prednisolone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
